These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31651865)

  • 1. A new method of intermittent lower dose of tolvaptan combined with fluid restriction to treat the syndrome of inappropriate antidiuresis: A case report.
    Yuan X; Pan H; Zhu H; Li J; Miao H; Ke X; Chen S
    Medicine (Baltimore); 2019 Oct; 98(43):e17586. PubMed ID: 31651865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A; McCormick L; Rahman M
    Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
    Shoaf SE; Bricmont P; Dandurand A
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome.
    Delbet JD; Parmentier C; Ulinski T
    Pediatr Nephrol; 2020 Jul; 35(7):1347-1350. PubMed ID: 32232633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
    J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report.
    Li T; Li GS
    Medicine (Baltimore); 2019 Jul; 98(27):e16229. PubMed ID: 31277136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion.
    Verbalis JG; Adler S; Schrier RW; Berl T; Zhao Q; Czerwiec FS;
    Eur J Endocrinol; 2011 May; 164(5):725-32. PubMed ID: 21317283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
    Arima H; Goto K; Motozawa T; Mouri M; Watanabe R; Hirano T; Ishikawa SE
    Endocr J; 2021 Jan; 68(1):17-29. PubMed ID: 32863282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA; Cranston IC
    BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
    Petereit C; Zaba O; Teber I; Lüders H; Grohé C
    BMC Pulm Med; 2013 Aug; 13():55. PubMed ID: 23987478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose.
    Torres AC; Wickham EP; Biskobing DM
    Endocr Pract; 2011; 17(4):e97-100. PubMed ID: 21613055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
    Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
    Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The syndrome of inappropriate antidiuresis (SIAD).
    Cuesta M; Thompson CJ
    Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):175-87. PubMed ID: 27156757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
    Meyer I; Frank D; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.